Supplementary Figure 2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Alvaro J. AlencarRaquel MalumbresGoldi A. KozloskiRanjana H. AdvaniNeha TalrejaShideh ChinichianJavier BrionesYasodha NatkunamLaurie H. SehnRandy D. GascoyneRob TibshiraniIzidore S. Lossos
0
Citation
0
Reference
10
Related Paper
Abstract:
Supplementary Figure 2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOPRead the full review for this Faculty Opinions recommended article: Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study.
Cite
Citations (0)
Supplementary Figure Legends 1-2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Cite
Citations (0)
Rituximab is a human-mouse chimeric monoclonal antibody that has demonstrated efficacy against non-Hodgkin's lymphoma (NHL). There is a powerful rationale for combining rituximab treatment with chemotherapeutic agents that have also shown efficacy in NHL, since the mechanisms of action are distinct and there is also evidence that rituximab may sensitize chemoresistant tumor cells to the actions of cytotoxic drugs. A study of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemoimmunotherapy has been carried out in 40 patients with low-grade NHL. In the 35 patients who completed the study, the overall response rate was 100%, with 63% achieving a complete response. Median time to progression has not yet been reached at 47.2+ months. Molecular analysis (polymerase chain reaction) showed that CHOP plus rituximab (unlike CHOP alone) could completely clear blood and bone marrow of cells containing the bcl-2 gene translocation, a molecular marker of NHL cells. Rituximab can therefore add to the efficacy of CHOP without significantly increasing toxicity. A further study is underway to determine whether similar efficacy with less overall toxicity can be achieved using rituximab in combination with fludarabine.
Chemoimmunotherapy
Cite
Citations (19)
Cite
Citations (5)
Objective To investigate and analyse rituximab combination with CHOP in patients with diffuse large B-cell lymphoma clinical effect. Method Select 86 cases of diffuse large B-cell lymphoma patients treatment in our hospital,randomly divided into two groups,which given rituximab with CHOP regimen combined treatment of 49 patients for the experimental group,and the remaining 37 cases only pure CHOP chemotherapy patients as the control group,the two groups of patients received six courses of treatment, the clinical effect of the two groups were compared. Results The control group efficiency was 86.49%,the experimental group efficiency of 93.88%,significantly higher than the control group(P 0.05). Conclusion Rituximab and CHOP regimen combined treatment of diffuse large B-cell lymphoma significant clinical effect,it is worth further promote in the use of clinical.
Regimen
Cite
Citations (0)
Cite
Citations (0)
Objective:To compare the efficacy of Rituximab with or without chemotherapy and CHOP alone on newly diagnosed patients with B-cell non-Hodgkin lymphoma(NHL), and to analyze their toxicities.Method:A total of 51 newly diagnosed patients with B-cell NHL were divided into 2 groups prospectively with concurrent control: 24 cases in Rituximab group were administered Rituximab with or without chemotherapy, the remaining 27 cases in CHOP group were treated with CHOP regimen only. All cases were evaluated after 3~6 courses.Result:The complete remission (CR) rate and totol response rate in Rituximab group were 83.3%(20/24) and 95.8%(23/24) respectively, while those corresponding rates in CHOP group were 55.6%(15/27) and 66.7%(18/27), respectively. The therapeutic efficacy differences between two groups showed statistical significance(P0.05). The 2-year overall survival rate was significantly higer in Rituximab group than in CHOP group(70.8% vs. 40.7%, P0.05).Conclusion:Comparing with CHOP group, Rituximab group showed higher therapeutic effects and 2-year overall survival rate. Rituximab can be used with good tolerance.
Regimen
Cite
Citations (0)
Supplementary Figure 2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Cite
Citations (0)
Supplementary Figure 2 from MicroRNAs Are Independent Predictors of Outcome in Diffuse Large B-Cell Lymphoma Patients Treated with R-CHOP
Cite
Citations (0)
Cite
Citations (0)